Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.46 |
| ▸ | AKT2 | P31751 | 9/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22674195 | 0.99 | AKT1 (0.47) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL22673508 | 0.98 | AKT1 (0.48) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL22674185 | 0.98 | AKT1 (0.48) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL22673683 | 0.96 | AKT1 (0.46) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL13599924 | 0.96 | AKT1 (0.50) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL25789286 | 0.95 | AKT1 (0.41) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL24479411 | 0.95 | AKT1 (0.45) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL22673681 | 0.94 | AKT1 (0.47) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL25789228 | 0.94 | AKT1 (0.45) | AKT1AKT2HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL13599932 | 0.93 | AKT1 (0.46) | AKT1AKT2HSP90AA1HSP90AB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169661-A1 | IMIDAZO NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO., LTD (CN) | 2022-06-02 | — | — | US | disclosed |
| WO-2020228430-A1 | IMIDAZO NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 广东阿格蕾雅光电材料有限公司 | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169661-A1 | IMIDAZO NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | HCN4, IPO8, HCN1 | AKT1 2630/4885AKT2 2749/4885HSP90AA1 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.